Based on customer requirements or product concept, we, R&D Center under PHIL International, work through organized process for each phase of developing and studying. The development scope can be flexibly enlarged or reduced upon a contract made with customers; gel and fill formula, trial encapsulation, scale-up to commercial batch, specifications and test procedures, manufacturing process, stability studies,
validation protocol and report, etc.

Our developments including on-going studies are specified as follow;

• Aceclofenac 100 mg
• Clotrimazole 100 mg, 500 mg
• Naproxen 250 mg
• Ursodeoxycholic acid 150 mg, 200 mg, 300 mg
• Dexibuprofen 300 mg
• Pamidronate 100 mg
• Clonixin lysinate 125 mg
• Artesunate 50 mg + Amodiaquine HCl 200 mg
• Piroxicam 20 mg
• Artemether 20 mg + Lumefantrine 120 mg
• Sildenafil 50 mg
• Artemether 80 mg + Lumefantrine 480 mg
• Dihydroxydibutyl ether 500 mg
• Donepezil 5 mg, 10mg
• Chewable softgel for dietary supplements